TNF‐α is a key proinflammatory cytokine in the pathogenesis of IBD, several anti‐TNF‐α agents have been approved with remarkable success.[68] As all anti‐TNF‐α agents currently in clinical use are administered intravenously or subcutaneously, the development of new oral anti‐TNF‐α agents is a popular direction. The gene discussed is TNF; the disease is inflammatory bowel disease.